Literature DB >> 20532540

Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.

Martin Jeffrey1, Gillian McGovern, Silvia Sisó, Lorenzo González.   

Abstract

The transmissible spongiform encephalopathies (TSEs) or prion diseases of animals are characterised by CNS spongiform change, gliosis and the accumulation of disease-associated forms of prion protein (PrP(d)). Particularly in ruminant prion diseases, a wide range of morphological types of PrP(d) depositions are found in association with neurons and glia. When light microscopic patterns of PrP(d) accumulations are correlated with sub-cellular structure, intracellular PrP(d) co-localises with lysosomes while non-intracellular PrP(d) accumulation co-localises with cell membranes and the extracellular space. Intracellular lysosomal PrP(d) is N-terminally truncated, but the site at which the PrP(d) molecule is cleaved depends on strain and cell type. Different PrP(d) cleavage sites are found for different cells infected with the same agent indicating that not all PrP(d) conformers code for different prion strains. Non-intracellular PrP(d) is full-length and is mainly found on plasma-lemmas of neuronal perikarya and dendrites and glia where it may be associated with scrapie-specific membrane pathology. These membrane changes appear to involve a redirection of the predominant axonal trafficking of normal cellular PrP and an altered endocytosis of PrP(d). PrP(d) is poorly excised from membranes, probably due to increased stabilisation on the membrane of PrP(d) complexed with other membrane ligands. PrP(d) on plasma-lemmas may also be transferred to other cells or released to the extracellular space. It is widely assumed that PrP(d) accumulations cause neurodegenerative changes that lead to clinical disease. However, when different animal prion diseases are considered, neurological deficits do not correlate well with any morphological type of PrP(d) accumulation or perturbation of PrP(d) trafficking. Non-PrP(d)-associated neurodegenerative changes in TSEs include vacuolation, tubulovesicular bodies and terminal axonal degeneration. The last of these correlates well with early neurological disease in mice, but such changes are absent from large animal prion disease. Thus, the proximate cause of clinical disease in animal prion disease is uncertain, but may not involve PrP(d).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20532540     DOI: 10.1007/s00401-010-0700-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

1.  In vitro generation of high-titer prions.

Authors:  Ronald A Shikiya; Jason C Bartz
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Axonal and transynaptic spread of prions.

Authors:  Harold Shearin; Richard A Bessen
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  Disease phenotype in sheep after infection with cloned murine scrapie strains.

Authors:  Silvia Sisó; Francesca Chianini; Sam L Eaton; Janey Witz; Scott Hamilton; Stuart Martin; Jeanie Finlayson; Yvonne Pang; Paula Stewart; Philip Steele; Mark P Dagleish; Wilfred Goldmann; Hugh W Reid; Martin Jeffrey; Lorenzo González
Journal:  Prion       Date:  2012-04-01       Impact factor: 3.931

4.  Non-amyloid and amyloid prion protein deposits in prion-infected mice differ in blockage of interstitial brain fluid.

Authors:  A Rangel; B Race; J Striebel; B Chesebro
Journal:  Neuropathol Appl Neurobiol       Date:  2013-04       Impact factor: 8.090

5.  Lesion profiling and subcellular prion localization of cervid chronic wasting disease in domestic cats.

Authors:  D M Seelig; A V Nalls; M Flasik; V Frank; S Eaton; C K Mathiason; E A Hoover
Journal:  Vet Pathol       Date:  2014-02-27       Impact factor: 2.221

6.  Ultrastructure and pathology of prion protein amyloid accumulation and cellular damage in extraneural tissues of scrapie-infected transgenic mice expressing anchorless prion protein.

Authors:  Brent Race; Martin Jeffrey; Gillian McGovern; David Dorward; Bruce Chesebro
Journal:  Prion       Date:  2017-07-31       Impact factor: 3.931

7.  PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2.

Authors:  Franc Llorens; Belén Ansoleaga; Paula Garcia-Esparcia; Saima Zafar; Oriol Grau-Rivera; Irene López-González; Rosi Blanco; Margarita Carmona; Jordi Yagüe; Carlos Nos; José Antonio Del Río; Ellen Gelpí; Inga Zerr; Isidre Ferrer
Journal:  Prion       Date:  2013-09-18       Impact factor: 3.931

8.  Plasma membrane invaginations containing clusters of full-length PrPSc are an early form of prion-associated neuropathology in vivo.

Authors:  Susan F Godsave; Holger Wille; Jason Pierson; Stanley B Prusiner; Peter J Peters
Journal:  Neurobiol Aging       Date:  2013-06       Impact factor: 4.673

9.  Using protein misfolding cyclic amplification generates a highly neurotoxic PrP dimer causing neurodegeneration.

Authors:  XiuJin Yang; LiFeng Yang; XiangMei Zhou; Sher Hayat Khan; HuiNuan Wang; XiaoMin Yin; Zhen Yuan; ZhiQi Song; WenYu Wu; DeMing Zhao
Journal:  J Mol Neurosci       Date:  2013-06-16       Impact factor: 3.444

10.  Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes.

Authors:  Heather R Bender; Sarah Kane; Mark D Zabel
Journal:  J Vis Exp       Date:  2016-07-23       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.